» Articles » PMID: 11164177

Immunohistochemical Assessment of Ki-67 in the Differential Diagnosis of Adrenocortical Tumors

Overview
Journal Urology
Specialty Urology
Date 2001 Feb 13
PMID 11164177
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To evaluate the utility of Ki-67 immunohistochemical analysis in the differential diagnosis between benign and malignant adrenocortical neoplasms.

Methods: Tissue specimens were obtained from 37 patients referred to our institute from 1990 to 1999. The indications for adrenalectomy were adrenal-dependent Cushing syndrome (n = 9), hyperandrogenism (n = 1), mineralocorticoid excess (n = 8), and nonfunctioning adrenal masses (n = 19). The histologic diagnosis was cortical adenoma in 26 of 37 patients and cortical carcinoma in the remainder. Normal adrenal glands were obtained from subjects who underwent radical nephrectomy because of initial renal carcinoma. Immunohistochemical analysis was performed using the monoclonal antibody anti-Ki-67 (clone MIB-1). The Ki-67 labeling index was expressed as the number of positive cells per 1000 cells.Results. The average Ki-67 expression was 2.0 per thousand +/- 1.2 per thousand (SD) in normal adrenal glands, 11.3 per thousand +/- 16.0 per thousand in adenomas, and 185.8 per thousand +/- 60.3 per thousand in carcinomas (P <0.0001). A threshold value of the Ki-67 labeling index between 70 per thousand and 90 per thousand reliably separated adenoma from carcinoma. A significant inverse correlation was found between Ki-67 expression and overall survival in patients with adrenal carcinoma (r = -0.74, P = 0.009).

Conclusions: Immunohistochemical assessment of the nuclear antigen Ki-67 can be useful in the differential diagnosis between adrenocortical adenoma and carcinoma. High levels of Ki-67 seem to indicate patients with adrenocortical cancer with a worse prognosis.

Citing Articles

The differential diagnosis of adrenocortical tumors: systematic review of Ki-67 and IGF2 and meta-analysis of Ki-67.

Oliveira S, Machado M, Sousa D, Pereira S, Pignatelli D Rev Endocr Metab Disord. 2025; .

PMID: 39890749 DOI: 10.1007/s11154-025-09945-w.


How to Differentiate Benign from Malignant Adrenocortical Tumors?.

Vietor C, Creemers S, van Kemenade F, van Ginhoven T, Hofland L, Feelders R Cancers (Basel). 2021; 13(17).

PMID: 34503194 PMC: 8431066. DOI: 10.3390/cancers13174383.


Differential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications.

Volante M, Rapa I, Metovic J, Napoli F, Tampieri C, Duregon E J Pers Med. 2021; 11(5).

PMID: 34066306 PMC: 8148197. DOI: 10.3390/jpm11050378.


Low Protein Expression of both and as Novel Negative Prognostic Markers of Adult Adrenocortical Carcinoma.

Brondani V, Lacombe A, Mariani B, Montenegro L, Soares I, Bezerra-Neto J Int J Mol Sci. 2021; 22(3).

PMID: 33513905 PMC: 7866180. DOI: 10.3390/ijms22031238.


Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.

Borges K, Pignatti E, Leng S, Kariyawasam D, Ruiz-Babot G, Ramalho F Oncogene. 2020; 39(30):5282-5291.

PMID: 32561853 PMC: 7378041. DOI: 10.1038/s41388-020-1358-5.